<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>10-FUSIDIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="S01AA13" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>If possible, stop the treatment with the HMG-COA Reductase Inhibitor before starting the treatment with fusidic acid or use another antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>10-FUSIDIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="S01AA13" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPEVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
